Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
OBJECTIVE
PAI-1 (plasminogen activator inhibitors-1) regulates plasminogen activation, and is related to tumour development. This study aims to test whether the promoter polymorphism in the PAI-1 gene is related to the aggressiveness of disease in prostate cancer.


METHODS
In the present study, Taqman SNP genotyping assay was used to detect PAI-1 4G/5G polymorphism in DNA from paraffin-embedded tissues of 98 Caucasian patients with prostate cancer.


RESULTS
The distribution of the genotypes is in Hardy-Weinberg equilibrium. The genotype had no statistically significant relationship with other prognostic factors. Similar risks for recurrence were seen in individuals with the 4G/4G and 4G/5G genotypes compared to those with 5G/5G genotype (odds ratio [OR] 2.65, 95% CI: 0.41-16.94, P = 0.30; OR = 2.19, 95% CI: 0.38-12.49, P = 0.38).


CONCLUSIONS
We concluded that PAI-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
Li
H
H
Department of Thoracic Surgery, Cancer Hospital/Cancer Institute, Fudan University, Shanghai, People's Republic of China.
Shinohara
E T
ET
Cai
Q
Q
Chen
H
H
Courtney
R
R
Cao
C
C
Wang
Z
Z
Teng
M
M
Zheng
W
W
Lu
B
B
D000368:Aged; D000369:Aged, 80 and over; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics*; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D018570:Risk Assessment; D012307:Risk Factors
D017395:Plasminogen Activator Inhibitor 1